EA201890868A1 - Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей - Google Patents

Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей

Info

Publication number
EA201890868A1
EA201890868A1 EA201890868A EA201890868A EA201890868A1 EA 201890868 A1 EA201890868 A1 EA 201890868A1 EA 201890868 A EA201890868 A EA 201890868A EA 201890868 A EA201890868 A EA 201890868A EA 201890868 A1 EA201890868 A1 EA 201890868A1
Authority
EA
Eurasian Patent Office
Prior art keywords
virulence
bacteria
faced
treatment
solid tumors
Prior art date
Application number
EA201890868A
Other languages
English (en)
Inventor
Симон Иттиг
Марлиз Амштуц
Кристоф Каспер
Гай Р. Корнелис
Original Assignee
Университет Базель
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Университет Базель filed Critical Университет Базель
Publication of EA201890868A1 publication Critical patent/EA201890868A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0258Escherichia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0275Salmonella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0291Yersinia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/104Pseudomonadales, e.g. Pseudomonas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

В настоящем изобретении предложен рекомбинантный штамм грамотрицательных бактерий с ослабленной вирулентностью для применения в способе лечения злокачественной солидной опухоли у субъекта.
EA201890868A 2015-11-19 2016-11-17 Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей EA201890868A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15195490 2015-11-19
PCT/EP2016/078084 WO2017085233A1 (en) 2015-11-19 2016-11-17 Virulence attenuated bacteria for treatment of malignant solid tumors

Publications (1)

Publication Number Publication Date
EA201890868A1 true EA201890868A1 (ru) 2018-12-28

Family

ID=54697464

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890868A EA201890868A1 (ru) 2015-11-19 2016-11-17 Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей

Country Status (24)

Country Link
US (1) US11166987B2 (ru)
EP (2) EP3903813A1 (ru)
JP (1) JP7060503B2 (ru)
KR (1) KR20180081583A (ru)
CN (1) CN108472348B (ru)
AU (1) AU2016358257B2 (ru)
BR (2) BR112018009753B1 (ru)
CA (1) CA3003563A1 (ru)
CY (1) CY1124564T1 (ru)
DK (1) DK3377094T3 (ru)
EA (1) EA201890868A1 (ru)
ES (1) ES2880431T3 (ru)
HK (1) HK1256137A1 (ru)
HR (1) HRP20211191T1 (ru)
HU (1) HUE055132T2 (ru)
IL (1) IL259052B2 (ru)
LT (1) LT3377094T (ru)
PL (1) PL3377094T3 (ru)
PT (1) PT3377094T (ru)
RS (1) RS62152B1 (ru)
SG (1) SG11201803643TA (ru)
SI (1) SI3377094T1 (ru)
WO (1) WO2017085233A1 (ru)
ZA (1) ZA201803902B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115960919A (zh) 2014-05-21 2023-04-14 巴塞尔大学 基于细菌的蛋白质递送
HUE051184T2 (hu) 2015-11-19 2021-03-01 Univ Basel Baktériumalapú fehérjeszállítás
PT3559022T (pt) 2016-12-20 2021-08-19 Univ Basel Distribuição de proteínas baseada em bactérias com virulência atenuada
KR102110993B1 (ko) * 2018-12-20 2020-05-14 한국생명공학연구원 클레브시엘라 아에로제네스(Klebsiella aerogenes) 균주를 유효성분으로 포함하는 암 진단, 예방 또는 치료용 조성물
KR20230098197A (ko) * 2020-10-27 2023-07-03 티3 파마슈티컬스 아게 세균 기반한 단백질 전달
CN114712496B (zh) * 2022-04-29 2023-10-13 中山大学·深圳 一种展示新抗原的细菌衍生外膜囊泡疫苗及制备方法和在制备癌症免疫治疗试剂盒中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965381A (en) * 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
WO2000002996A2 (en) 1998-07-10 2000-01-20 Cornell Research Foundation, Inc. Recombinant constructs and systems for secretion of proteins via type iii secretion systems
WO2002026819A2 (en) 2000-09-26 2002-04-04 Roger Williams Hospital Recombinant bcg vaccines for the prevention and treatment of cancer
WO2002077249A2 (en) * 2001-03-26 2002-10-03 Universite Catholique De Louvain Type iii bacterial strains for use in medicine
EP1565185A4 (en) 2002-11-07 2011-01-05 Technion Res & Dev Foundation NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH
FR2862312B1 (fr) 2003-11-13 2006-02-17 Univ Grenoble 1 Outil de transfert et de production de proteines mettant en oeuvre le systeme de secretion de type iii de pseudomonas
JP2009510169A (ja) 2005-10-04 2009-03-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 細菌抗原送達系を用いた免疫応答を刺激するための方法
WO2008019183A2 (en) 2006-05-18 2008-02-14 The Regents Of The University Of California Biopolymer and protein production using type iii secretion systems of gram negative bacteria
TW200819540A (en) * 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
AU2009226972B2 (en) 2008-03-17 2014-05-29 Gerhard Heusipp YopM as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
US10709784B2 (en) 2011-06-08 2020-07-14 Chelation Partners Incorporated Metal chelating compositions and methods for controlling the growth or activities of a living cell or organism
US9127284B2 (en) * 2012-05-04 2015-09-08 The University Of Hong Kong Modified bacteria and their uses thereof for the treatment of cancer or tumor
CN113563478A (zh) 2013-09-24 2021-10-29 梅迪塞纳医疗股份有限公司 白介素-4受体结合融合蛋白及其应用
US10143743B2 (en) 2013-11-18 2018-12-04 Yale University Non-replicating bacterial nanoparticle delivery system and methods of use
CN115960919A (zh) 2014-05-21 2023-04-14 巴塞尔大学 基于细菌的蛋白质递送
HUE051184T2 (hu) 2015-11-19 2021-03-01 Univ Basel Baktériumalapú fehérjeszállítás
PT3559022T (pt) 2016-12-20 2021-08-19 Univ Basel Distribuição de proteínas baseada em bactérias com virulência atenuada

Also Published As

Publication number Publication date
RS62152B1 (sr) 2021-08-31
AU2016358257A1 (en) 2018-05-10
BR112018009753A2 (pt) 2018-11-13
ES2880431T3 (es) 2021-11-24
EP3377094A1 (en) 2018-09-26
CN108472348A (zh) 2018-08-31
LT3377094T (lt) 2021-08-10
HK1256137A1 (zh) 2019-09-13
PL3377094T3 (pl) 2021-12-13
JP2019500026A (ja) 2019-01-10
PT3377094T (pt) 2021-07-08
EP3903813A1 (en) 2021-11-03
SI3377094T1 (sl) 2021-09-30
CA3003563A1 (en) 2017-05-26
IL259052B2 (en) 2024-03-01
SG11201803643TA (en) 2018-06-28
JP7060503B2 (ja) 2022-04-26
HRP20211191T1 (hr) 2021-10-29
EP3377094B1 (en) 2021-04-28
IL259052A (en) 2018-07-31
BR112018009753B1 (pt) 2024-02-20
WO2017085233A1 (en) 2017-05-26
US20190015497A1 (en) 2019-01-17
KR20180081583A (ko) 2018-07-16
BR112018009753A8 (pt) 2019-02-26
HUE055132T2 (hu) 2021-11-29
BR122023024697A2 (pt) 2023-12-26
DK3377094T3 (da) 2021-08-02
AU2016358257B2 (en) 2023-08-17
CN108472348B (zh) 2022-12-27
US11166987B2 (en) 2021-11-09
IL259052B1 (en) 2023-11-01
ZA201803902B (en) 2019-03-27
CY1124564T1 (el) 2022-07-22

Similar Documents

Publication Publication Date Title
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
MD3209381T2 (ro) Compoziții care conțin tulpini bacteriene
EA201890868A1 (ru) Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
EA201991157A1 (ru) Доставка белков на основе бактерий, аттенуированных по вирулентности
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX2017001154A (es) Metodos y combinaciones terapeuticas para tratar tumores.
MX2020011772A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
MX2019002925A (es) Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer.
PH12018500578A1 (en) Methods of treating inflammatory diseases
EA201991818A1 (ru) Лечение рака
MX2020006297A (es) Variantes de cd19.
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
NZ740817A (en) Pcna inhibitors
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
MX2017016346A (es) Metodos de tratamiento con taselisib.
MX2019006694A (es) Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.
EP3371211A4 (en) METHOD FOR THE TREATMENT OF TUMORS AND CANCER AND IDENTIFICATION OF CANDIDATE PATIENTS FOR SUCH TREATMENT
CY1125266T1 (el) To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων
EA202192163A1 (ru) Лечение рака